Long-term outcomes of self-expanding versus balloon-expandable transcatheter aortic valves: Insights from the OBSERVANT study.
aortic valve disease
comparative effectiveness/patient centered outcomes research
transcatheter valve implantation
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
15 11 2021
15 11 2021
Historique:
received:
04
02
2021
accepted:
19
03
2021
pubmed:
14
4
2021
medline:
15
12
2021
entrez:
13
4
2021
Statut:
ppublish
Résumé
To compare clinical outcomes of balloon-expandable (BE) and self-expanding (SE) transcatheter aortic valves (TAVs) up to 5 years. To date, no robust, comparative data of BE and SE TAVs at long-term are available. We considered a total of 1,440 patients enrolled in the multicenter OBSERVANT study and undergoing transfemoral transcatheter aortic valve implantation (TF-TAVI) with either supra-annular SE (n = 830, 57.6%) and intra-annular BE (n = 610, 42.4%) valves. Clinical outcomes of the two groups were compared after adjustment using inverse probability of treatment weighting (IPTW) and confirmed by sensitivity analysis with propensity score matching. Patients receiving SE valve showed a higher all-cause mortality at 5 years (Kaplan-Meier estimates 52.3% vs. 47.7%; Hazard ratio [HR] 1.18, 95% confidence interval [CI] 1.01-1.38, p = .04). Landmark analyses showed that there was a not statistically significant reversal of risk excess against the BE group starting from 3 years after TAVI (3-5 years HR 0.97, 95% CI 0.76-1.25, p = .86). Post-procedural, moderate/severe paravalvular regurgitation (PVR)(HR 1.46, 95% CI 1.14-1.87; p < .01) and acute kidney injury (AKI)(HR 3.89, 95% CI 2.47-6.38; p < .01) showed to be independent predictors of 5-year all-cause mortality in multivariable analysis. Considering the intrinsic limitations of the OBSERVANT study, we found that patients undergoing TF-TAVI with a supra-annular SE valve had a higher all-cause mortality compared to those receiving an intra-annular BE valve at 5 years. A late catch up phenomenon of patients receiving the BE valve was observed beyond 3 years. Post-procedural moderate/severe PVR seems to play a crucial role in determining this finding. Comparative studies of new generation devices with longer follow-up are needed to evaluate the benefit of each specific TAV type.
Sections du résumé
OBJECTIVES
To compare clinical outcomes of balloon-expandable (BE) and self-expanding (SE) transcatheter aortic valves (TAVs) up to 5 years.
BACKGROUND
To date, no robust, comparative data of BE and SE TAVs at long-term are available.
METHODS
We considered a total of 1,440 patients enrolled in the multicenter OBSERVANT study and undergoing transfemoral transcatheter aortic valve implantation (TF-TAVI) with either supra-annular SE (n = 830, 57.6%) and intra-annular BE (n = 610, 42.4%) valves. Clinical outcomes of the two groups were compared after adjustment using inverse probability of treatment weighting (IPTW) and confirmed by sensitivity analysis with propensity score matching.
RESULTS
Patients receiving SE valve showed a higher all-cause mortality at 5 years (Kaplan-Meier estimates 52.3% vs. 47.7%; Hazard ratio [HR] 1.18, 95% confidence interval [CI] 1.01-1.38, p = .04). Landmark analyses showed that there was a not statistically significant reversal of risk excess against the BE group starting from 3 years after TAVI (3-5 years HR 0.97, 95% CI 0.76-1.25, p = .86). Post-procedural, moderate/severe paravalvular regurgitation (PVR)(HR 1.46, 95% CI 1.14-1.87; p < .01) and acute kidney injury (AKI)(HR 3.89, 95% CI 2.47-6.38; p < .01) showed to be independent predictors of 5-year all-cause mortality in multivariable analysis.
CONCLUSIONS
Considering the intrinsic limitations of the OBSERVANT study, we found that patients undergoing TF-TAVI with a supra-annular SE valve had a higher all-cause mortality compared to those receiving an intra-annular BE valve at 5 years. A late catch up phenomenon of patients receiving the BE valve was observed beyond 3 years. Post-procedural moderate/severe PVR seems to play a crucial role in determining this finding. Comparative studies of new generation devices with longer follow-up are needed to evaluate the benefit of each specific TAV type.
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1167-1176Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705.
Popma JJ, Michael Deeb G, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706-1715.
Chieffo A, Buchanan GL, Van Mieghem NM, et al. Transcatheter aortic valve implantation with the Edwards SAPIEN versus the Medtronic CoreValve Revalving system devices: a multicenter collaborative study: the PRAGMATIC plus initiative (pooled RotterdAm-Milano-Toulouse in collaboration). JACC. 2013;61:830-836.
Kasel AM, Cassese S, Ischinger T, et al. A prospective, non-randomized comparison of SAPIEN XT and CoreValve implantation in two sequential cohorts of patients with severe aortic stenosis. Am J Cardiovasc Dis. 2014;4:87-99.
Abdel-Wahab M, Comberg T, Büttner HJ, et al. Aortic regurgitation after transcatheter aortic valve implantation with balloon- and self-expandable prostheses: a pooled analysis from a 2-center experience. JACC Cardiovasc Interv. 2014;7:284-292.
Kaya D, Tanriverdi Z, Dursun H, Colluoglu T. Echocardiographic outcomes of self-expandable CoreValve versus balloon-expandable Edwards SAPIEN XT valves: the comparison of two bioprosthesis implanted in a single Centre. Int J Cardiovasc Imaging. 2016;32:1371-1378.
Kiramijyan S, Magalhaes MA, Koifman E, et al. Aortic regurgitation in patients undergoing Transcatheter aortic valve replacement with the self-expanding corevalve versus the balloon-expandable SAPIEN XT valve. Am J Cardiol. 2016;117:1502-1510.
Tarantini G, Purita PAM, D'Onofrio A, et al. Long-term outcomes and prosthesis performance after transcatheter aortic valve replacement: results of self-expandable and balloon-expandable transcatheter heart valves. Ann Cardiothorac Surg. 2017;6:473-483.
D'Errigo P, Barbanti M, Ranucci M, et al. Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis: results from an intermediate risk propensity-matched population of the Italian OBSERVANT study. Int J Cardiol. 2013;167:1945-1952.
Tamburino C, Barbanti M, D'Errigo P, et al. 1-year outcomes after Transfemoral Transcatheter or surgical aortic valve replacement. J Am Coll Cardiol. 2015;66:804-812.
Barbanti M, Tamburino C, D'Errigo P, et al. Five-year outcomes of Transfemoral Transcatheter aortic valve replacement or surgical aortic valve replacement in a real world population. Circ Cardiovasc Interv. 2019;12:1-9.
Barbanti M, Petronio AS, Ettori F, et al. 5-year outcomes after Transcatheter aortic valve implantation with CoreValve prosthesis. JACC Cardiovasc Interv. 2015;8:1084-1091.
Gerckens U, Tamburino C, Bleiziffer S, et al. Final 5-year clinical and echocardiographic results for treatment of severe aortic stenosis with a self-expanding bioprosthesis from the ADVANCE study. Eur Heart J. 2017;38:2729-2738.
Toggweiler S, Humphries KH, Lee M, et al. 5-year outcome after Transcatheter aortic valve implantation. J Am Coll Cardiol. 2013;61:413-419.
Duncan A, Ludman P, Banya W, et al. Long-term outcomes after Transcatheter aortic valve replacement in high-risk patients with severe aortic stenosis. JACC Cardiovasc Interv. 2015;8:645-653.
Makkar RR, Thourani VH, Mack MJ, et al. PARTNER 2 investigators. Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med. 2020;382:799-809.
Gleason TG, Reardon MJ, Popma JJ, et al. CoreValve U.S. pivotal high risk trial clinical investigators. 5-year outcomes of self-expanding Transcatheter versus surgical aortic valve replacement in high-risk patients. J Am Coll Cardiol. 2018;72:2687-2696. http://www.ncbi.nlm.nih.gov/pubmed/30249462.
Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al. Acc/aha/esc guidelines for the management of patients with supraventricular arrhythmias*-executive summary a report of the american college of cardiology/american heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias). Circulation; 2003;108(15):1871-1909.
Van BE, Vincent F, Labreuche J, et al. Balloon-expandable versus self-expanding Transcatheter aortic valve replacement. Circulation. 2020;141:243-259.
Abdel-Wahab M, Landt M, Neumann F-J, et al. 5-year outcomes after TAVR with balloon-expandable versus self-expanding valves. JACC Cardiovasc Interv. 2020;13:1071-1082.
Elgendy IY, Gad MM, Mahmoud AN, et al. Meta-analysis comparing outcomes of self-expanding versus balloon-expandable valves for Transcatheter aortic valve implantation. Am J Cardiol. 2020;128:202-209. https://linkinghub.elsevier.com/retrieve/pii/S0002914920304823.
Barbanti M, Webb JG, Dvir D, Prendergast BD. Residual challenges in TAVI: moving forward. EuroIntervention. 2019;15:857-866.
Makkar RR, Blanke P, Leipsic J, et al. Subclinical leaflet thrombosis in Transcatheter and surgical bioprosthetic valves. J Am Coll Cardiol. 2020;75:3003-3015.
Kliuk-Ben Bassat O, Finkelstein A, Bazan S, et al. Acute kidney injury after transcatheter aortic valve implantation and mortality risk-long-term follow-up. Nephrol Dial Transplant. 2020;35:433-438.
Arnold SV, Manandhar P, Vemulapalli S, et al. Impact of short-term complications of transcatheter aortic valve replacement on longer-term outcomes: results from the STS/ACC Transcatheter valve therapy registry. Eur Hear J - Qual Care Clin Outcomes. 2021;7:208-213.
Van Belle E, Juthier F, Susen S, et al. Postprocedural aortic regurgitation in balloon-expandable and self-expandable Transcatheter aortic valve replacement procedures. Circulation. 2014;129:1415-1427.
Abdel-Wahab M, Mehilli J, Frerker C, et al. CHOICE investigators. Comparison of balloon-expandable vs self-expandable valves in patients undergoing transcatheter aortic valve replacement: the CHOICE randomized clinical trial. JAMA. 2014;311:1503-1514. http://www.ncbi.nlm.nih.gov/pubmed/24682026.
Tamburino C, Capodanno D, Ramondo A, et al. Incidence and predictors of early and late mortality after Transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation. 2011;123:299-308.
Blanke P, Pibarot P, Hahn R, et al. Computed tomography-based oversizing degrees and incidence of paravalvular regurgitation of a new generation Transcatheter heart valve. JACC Cardiovasc Interv. 2017;10:810-820.
Barbanti M, Buccheri S, Rodés-Cabau J, et al. Transcatheter aortic valve replacement with new-generation devices: a systematic review and meta-analysis. Int J Cardiol. 2017;245:83-89.